415 related articles for article (PubMed ID: 29413525)
1. Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5.
Brody AH; Strittmatter SM
Adv Pharmacol; 2018; 82():293-323. PubMed ID: 29413525
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.
Um JW; Kaufman AC; Kostylev M; Heiss JK; Stagi M; Takahashi H; Kerrisk ME; Vortmeyer A; Wisniewski T; Koleske AJ; Gunther EC; Nygaard HB; Strittmatter SM
Neuron; 2013 Sep; 79(5):887-902. PubMed ID: 24012003
[TBL] [Abstract][Full Text] [Related]
3. Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
Crestini A; Santilli F; Martellucci S; Carbone E; Sorice M; Piscopo P; Mattei V
J Alzheimers Dis; 2022; 85(2):503-518. PubMed ID: 34864675
[TBL] [Abstract][Full Text] [Related]
4. Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
Haas LT; Strittmatter SM
J Biol Chem; 2016 Aug; 291(33):17112-21. PubMed ID: 27325698
[TBL] [Abstract][Full Text] [Related]
5. Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.
Salazar SV; Strittmatter SM
Biochem Biophys Res Commun; 2017 Feb; 483(4):1143-1147. PubMed ID: 27639648
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.
Salazar SV; Cox TO; Lee S; Brody AH; Chyung AS; Haas LT; Strittmatter SM
J Neurosci; 2019 Jan; 39(4):758-772. PubMed ID: 30518596
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Amyloid β Oligomer Binding to Neurons and Neurotoxicity by the Prion Protein-mGluR5 Complex.
Beraldo FH; Ostapchenko VG; Caetano FA; Guimaraes AL; Ferretti GD; Daude N; Bertram L; Nogueira KO; Silva JL; Westaway D; Cashman NR; Martins VR; Prado VF; Prado MA
J Biol Chem; 2016 Oct; 291(42):21945-21955. PubMed ID: 27563063
[TBL] [Abstract][Full Text] [Related]
8. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
9. Conditional Deletion of
Salazar SV; Gallardo C; Kaufman AC; Herber CS; Haas LT; Robinson S; Manson JC; Lee MK; Strittmatter SM
J Neurosci; 2017 Sep; 37(38):9207-9221. PubMed ID: 28842420
[TBL] [Abstract][Full Text] [Related]
10. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).
Haas LT; Kostylev MA; Strittmatter SM
J Biol Chem; 2014 Oct; 289(41):28460-77. PubMed ID: 25148681
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers.
Jarosz-Griffiths HH; Corbett NJ; Rowland HA; Fisher K; Jones AC; Baron J; Howell GJ; Cowley SA; Chintawar S; Cader MZ; Kellett KAB; Hooper NM
J Biol Chem; 2019 Apr; 294(17):7085-7097. PubMed ID: 30872401
[TBL] [Abstract][Full Text] [Related]
13. Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer's disease.
Marcatti M; Fracassi A; Montalbano M; Natarajan C; Krishnan B; Kayed R; Taglialatela G
Cell Mol Life Sci; 2022 Apr; 79(4):222. PubMed ID: 35377002
[TBL] [Abstract][Full Text] [Related]
14. Neuronal transcriptome, tau and synapse loss in Alzheimer's knock-in mice require prion protein.
Stoner A; Fu L; Nicholson L; Zheng C; Toyonaga T; Spurrier J; Laird W; Cai Z; Strittmatter SM
Alzheimers Res Ther; 2023 Nov; 15(1):201. PubMed ID: 37968719
[TBL] [Abstract][Full Text] [Related]
15. Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.
Smith LM; Strittmatter SM
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 27940601
[TBL] [Abstract][Full Text] [Related]
16. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
Viola KL; Klein WL
Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
[TBL] [Abstract][Full Text] [Related]
18. Targeting Fyn Kinase in Alzheimer's Disease.
Nygaard HB
Biol Psychiatry; 2018 Feb; 83(4):369-376. PubMed ID: 28709498
[TBL] [Abstract][Full Text] [Related]
19. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.
Haas LT; Salazar SV; Smith LM; Zhao HR; Cox TO; Herber CS; Degnan AP; Balakrishnan A; Macor JE; Albright CF; Strittmatter SM
Cell Rep; 2017 Jul; 20(1):76-88. PubMed ID: 28683325
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
